Defilade Capital Management’s Mereo BioPharma MREO Stock Holding History

Defilade Capital Management’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.4M	Hold	7,558,756	–	–	0.32%	39
2026 Q1	$2.49M	Buy	+7,558,756	New	+$3.24M	0.35%	31

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Ishara Investments Los Angeles, California $136M AUM

Defilade Capital Management's MREO Position: Q2 2026 in Review

Defilade Capital Management held its Mereo BioPharma (MREO) position steady in Q2 2026 at 7,558,756 shares worth $2.4M. The position accounts for 0.32% of the portfolio, ranked #39.

Defilade Capital Management first reported a position in MREO in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.49M in Q1 2026. 61 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

Defilade Capital Management held 7,558,756 shares of Mereo BioPharma worth $2.4M as of Q2 2026.
Defilade Capital Management left its Mereo BioPharma share count unchanged in Q2 2026.
Mereo BioPharma made up 0.32% of Defilade Capital Management's portfolio in Q2 2026, its #39 holding.
Defilade Capital Management first reported a position in Mereo BioPharma in Q1 2026 and has held it in 2 quarters since.
Defilade Capital Management's Mereo BioPharma position peaked at $2.49M in Q1 2026.
61 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on Defilade Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.